Please ensure Javascript is enabled for purposes of website accessibility

New Swab for COVID-19 Test Doesn't Need to Be Shoved All the Way Up the Nose

By Brian Orelli, PhD - Apr 17, 2020 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Using the spun synthetic swab, people can collect their own test samples from the front of their nostrils.

"They stick these swabs up your nose. When I say up your nose, I'm talking way further up your nose than I knew the nose ever goes. I have a new understanding of my face now," said personal finance podcaster Paula Pant of getting the COVID-19 test. "It's an incredibly, incredibly awkward test."

Soon, however, those seeking to find out whether they have caught the coronavirus may not have to learn the hard way that their nasal passages travel halfway to their brain. The Food and Drug Administration has endorsed a new type of spun synthetic swab developed by U.S. Cotton, a subsidiary of privately held Parkdale-Mills, that can effectively collect samples closer to the front of the nose.

A study led by UnitedHealth Group (UNH -0.73%) in conjunction with Quantigen and the Bill and Melinda Gates Foundation showed that when patients self-administered the swab to the front part of the nostril and mid-nose, they collected samples that allowed tests to successfully detect the coronavirus.  The study also validated the use of readily available saline solution to transport the samples rather than traditional viral transport media, which are in short supply.

Man getting a nasal swab by a healthcare worker

Image source: Getty Images.

Last month, UnitedHealth released a study showing that people could effectively collect their own COVID-19 test samples, but that was using foam swabs, which aren't as readily available as polyester swabs.

"We appreciate the work of these collaborators to consider how these test supplies could be broadly distributed to meet not only the testing needs of the United States but also global needs around the pandemic. All of these actions by these American organizations will help continue to expand our testing capability," FDA Commissioner Stephen Hahn said in a statement.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
$542.13 (-0.73%) $-3.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.